Vascepa was just approved by the FDA to reduce cardiovascular risk among certain patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy. In a recent study Vascepa significantly reduced the risk of death due to cardiovascular causes, heart attack, and stroke in patients who remained at increased risk despite statin therapy.
